索磷布韦/维帕他韦/伏西瑞韦在印度用于索磷布韦治疗无应答的基因3型丙型肝炎病毒感染的应用。
Use of Sofosbuvir/Velpatasvir/Voxilaprevir for Sofosbuvir Nonresponder Genotype 3 HCV Infection in India.
作者信息
Tiwari Prachi, Katiyar Harshita, Rai Praveer, Goel Amit
机构信息
Department of Gastroenterology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India.
出版信息
J Clin Exp Hepatol. 2022 Mar-Apr;12(2):669-671. doi: 10.1016/j.jceh.2021.06.023. Epub 2021 Jul 3.
Abstract
In India, hepatitis C virus (HCV) infection is treated with sofosbuvir in combination with NS5A inhibitor (Daclatasvir, Ledipasvir, or Velpatasvir). A small proportion of them fail to achieve sustained virological response at 12 weeks (SVR12) and need retreatment. Triple-drug combination (Sofosbuvir/Velpatasvir/Voxilaprevir) is one of the options for retreatment. Here we describe a patient with cirrhosis and genotype 3a infection who was successfully treated with a triple-drug combination after relapse with two courses of Sofosbuvir-containing regimens.
摘要
在印度，丙型肝炎病毒（HCV）感染采用索磷布韦联合NS5A抑制剂（达卡他韦、来迪派韦或维帕他韦）进行治疗。其中一小部分患者在12周时未能实现持续病毒学应答（SVR12），需要重新治疗。三联药物组合（索磷布韦/维帕他韦/伏西瑞韦）是重新治疗的选择之一。在此，我们描述了一名患有肝硬化且感染基因3a型的患者，该患者在含索磷布韦方案的两个疗程复发后，采用三联药物组合成功治愈。
相似文献
1
Use of Sofosbuvir/Velpatasvir/Voxilaprevir for Sofosbuvir Nonresponder Genotype 3 HCV Infection in India.
J Clin Exp Hepatol. 2022 Mar-Apr;12(2):669-671. doi: 10.1016/j.jceh.2021.06.023. Epub 2021 Jul 3.
2
Sofosbuvir/Velpatasvir/Voxilaprevir for Hepatitis C Virus Retreatment in Difficult-to-treat Patients: A Real-life Observational Study from India.
J Clin Exp Hepatol. 2024 Mar-Apr;14(2):101314. doi: 10.1016/j.jceh.2023.101314. Epub 2023 Dec 9.
3
Safety and efficacy of sofosbuvir-velpatasvir-voxilaprevir for re-treatment of chronic hepatitis C virus infection in patients with previous direct-acting antiviral treatment failure in Rwanda (SHARED-3): a single-arm trial.
Lancet Gastroenterol Hepatol. 2022 Jun;7(6):542-551. doi: 10.1016/S2468-1253(21)00399-X. Epub 2022 Mar 3.
4
Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection.
N Engl J Med. 2017 Jun 1;376(22):2134-2146. doi: 10.1056/NEJMoa1613512.
5
Sofosbuvir/Velpatasvir/Voxilaprevir: A Review in Chronic Hepatitis C.
Drugs. 2018 Apr;78(5):577-587. doi: 10.1007/s40265-018-0895-5.
6
Sofosbuvir-velpatasvir-voxilaprevir with or without ribavirin in direct-acting antiviral-experienced patients with genotype 1 hepatitis C virus.
Hepatology. 2017 Jun;65(6):1803-1809. doi: 10.1002/hep.29130. Epub 2017 May 3.
7
Deferred treatment with sofosbuvir-velpatasvir-voxilaprevir for patients with chronic hepatitis C virus who were previously treated with an NS5A inhibitor: an open-label substudy of POLARIS-1.
Lancet Gastroenterol Hepatol. 2018 Aug;3(8):559-565. doi: 10.1016/S2468-1253(18)30118-3. Epub 2018 May 31.
8
Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C previously treated with DAAs.
J Hepatol. 2019 Oct;71(4):666-672. doi: 10.1016/j.jhep.2019.06.002. Epub 2019 Jun 14.
9
High efficacy of resistance-guided retreatment of HCV patients failing NS5A inhibitors in the real world.
J Hepatol. 2019 Nov;71(5):876-888. doi: 10.1016/j.jhep.2019.06.022. Epub 2019 Jul 4.
10
Sofosbuvir-velpatasvir-voxilaprevir in adolescents 12 to 17 years old with HCV infection.
Hepatology. 2022 Aug;76(2):445-455. doi: 10.1002/hep.32393. Epub 2022 Mar 1.
引用本文的文献
1
Sofosbuvir/Velpatasvir/Voxilaprevir for Hepatitis C Virus Retreatment in Difficult-to-treat Patients: A Real-life Observational Study from India.
J Clin Exp Hepatol. 2024 Mar-Apr;14(2):101314. doi: 10.1016/j.jceh.2023.101314. Epub 2023 Dec 9.
2
Hepatitis C Retreatment With First-Line Direct Acting Antiviral Drugs.
J Clin Exp Hepatol. 2023 Sep-Oct;13(5):736-741. doi: 10.1016/j.jceh.2023.03.007. Epub 2023 Mar 24.
本文引用的文献
1
Real-world re-treatment outcomes of direct-acting antiviral therapy failure in patients with chronic hepatitis C.
J Med Virol. 2021 Aug;93(8):4982-4991. doi: 10.1002/jmv.26971. Epub 2021 Apr 13.
2
Resistance analysis and treatment outcomes in hepatitis C virus genotype 3-infected patients within the Italian network VIRONET-C.
Liver Int. 2021 Aug;41(8):1802-1814. doi: 10.1111/liv.14797. Epub 2021 Feb 8.
3
Acute hepatitis C treatment in advanced renal failure using 8 weeks of pan-genotypic daclatasvir and reduced-dose sofosbuvir.
Nephrol Dial Transplant. 2021 Sep 27;36(10):1867-1871. doi: 10.1093/ndt/gfaa187.
4
Decentralized care with generic direct-acting antivirals in the management of chronic hepatitis C in a public health care setting.
J Hepatol. 2019 Dec;71(6):1076-1085. doi: 10.1016/j.jhep.2019.07.006. Epub 2019 Jul 17.
5
Retreatment of Hepatitis C Virus-Infected Patients with Direct-Acting Antiviral Failures.
Semin Liver Dis. 2019 Jul;39(3):354-368. doi: 10.1055/s-0039-1687823. Epub 2019 Apr 30.
6
Burden of hepatitis C virus infection in India: A systematic review and meta-analysis.
J Gastroenterol Hepatol. 2019 Feb;34(2):321-329. doi: 10.1111/jgh.14466. Epub 2018 Sep 26.
7
Daclatasvir and reduced-dose sofosbuvir: An effective and pangenotypic treatment for hepatitis C in patients with estimated glomerular filtration rate <30 mL/min.
Nephrology (Carlton). 2019 Mar;24(3):316-321. doi: 10.1111/nep.13222.
8
Patterns of Resistance-Associated Substitutions in Patients With Chronic HCV Infection Following Treatment With Direct-Acting Antivirals.
Gastroenterology. 2018 Mar;154(4):976-988.e4. doi: 10.1053/j.gastro.2017.11.007. Epub 2017 Nov 13.
9
Treatment of chronic genotype-3 hepatitis C virus infection using direct-acting antiviral agents: An Indian experience.
Indian J Gastroenterol. 2017 May;36(3):227-234. doi: 10.1007/s12664-017-0763-3. Epub 2017 Jun 28.
10
Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection.
N Engl J Med. 2017 Jun 1;376(22):2134-2146. doi: 10.1056/NEJMoa1613512.
Zotero 插件